IMA Life, one of the three pharma divisions of IMA Group and global leader in advanced, aseptic pharmaceutical process and production solutions, announces a strategic partnership with RheaVita, a pioneer in controlled, continuous freeze-drying technology for biopharmaceuticals. This partnership includes both a financial investment in RheaVita by IMA Life and ongoing support to expand the development and commercialization of RheaVita’s cutting-edge technology for the global market.
IMA Life’s commitment to technological innovation and excellence aligns closely with RheaVita’s objectives, and the two companies are focused on driving impactful advancements in the freeze-drying market. This partnership aligns with IMA Life’s mission to support innovative technologies that enhance production efficiency and ensure consistent quality in life-saving therapies. The common aim is to establish new standards in freeze-drying to benefit the global pharmaceutical industry and patients worldwide.




















